CN113144130A

CN113144130A - Preparation method of gastritis eliminating pills

Info

Publication number: CN113144130A
Application number: CN202110269367.3A
Authority: CN
Inventors: 阳吉长
Original assignee: Guyitang Hunan Health Technology Co ltd
Current assignee: Guyitang Hunan Health Technology Co ltd
Priority date: 2021-03-12
Filing date: 2021-03-12
Publication date: 2021-07-23

Abstract

The invention belongs to the technical field of preparation methods of Chinese herbal medicines, and discloses a preparation method of a gastritis eliminating pill. The method controls the water content of each raw material within a certain range by utilizing a drying technology, and ensures the content of effective components; the raw materials are crushed by using a crushing technology, so that the yield of finished products is improved, and meanwhile, the effective components of the raw materials of the Chinese herbal medicines are not damaged; the addition of the solidifying agent and the solvent facilitates the transportation and the use of the obtained finished product, prolongs the service life of the finished product, and has strong safety and stability. The method is simple and convenient to implement and is suitable for mass production. The prescription takes the cortex magnoliae officinalis, the cortex cinnamomi and the rhizoma coptidis as monarch drugs, the fructus amomi, the radix paeoniae alba, the fructus aurantii stir-fried with bran, the cubeb, the myrobalan, the cuttlebone sheath fried with bran, the prepared fructus mume and the radix codonopsis as adjuvant drugs, and the liquorice tablets as conductant drugs, so that the principle of strengthening the spleen and the stomach and promoting the circulation of qi and relieving pain in treatment is adopted, the proliferation of gastric mucosa cells is promoted, the secretion of gastric acid is increased, the atrophy of the stomach is relieved, and the gastrointestinal function of a patient is effectively recovered.

Description

Preparation method of gastritis eliminating pills

Technical Field

The invention belongs to the technical field of preparation methods of Chinese herbal medicines, and particularly relates to a preparation method of a gastritis eliminating pill.

Background

Gastritis is a gastric mucositis lesion caused by various etiological factors, and is a common disease and a chronic disease of the digestive system. Gastric ulcers are primarily associated with an imbalance between mucosal damage and mucosal self-defense repair. Chronic gastritis and gastric ulcer are the most common and frequent diseases in the digestive system, and are chronic diseases which are puzzled and difficult to master in diagnosis and treatment. About 45% of people often have symptoms of stomach pain, fullness, acid regurgitation, belching, heartburn, vomiting, inappetence and the like, and are mostly chronic gastritis and gastric ulcer. The incidence rate of chronic gastritis is the top of various stomach diseases, which accounts for about 90% of patients in outpatient gastroscopy, and the incidence rate is higher when the patients are older, especially the patients of middle-aged and old people are more common.

Among patients who receive gastroscopy, 80% to 90% of patients have chronic gastritis and gastric ulcer with different degrees. The gastric ulcer is obviously seasonal, is easy to occur in 11 and 12 months and 1 to 3 months with sudden temperature change and cold weather, is stable in temperature in summer and has the lowest morbidity. With the age, the relative incidence of gastric ulcer can be obviously increased, the peak age of the incidence is 50-60 years, and the proportion of male to female is 3.6: 1, the recurrence rate is 60% to 80%, and about 10% of people have suffered from the disease at some time during their lifetime.

The morbidity of people in all countries in the world is obviously different, and different periods, geography, climate, nationality, heredity, life habits and the like all have certain influence on the epidemiology of the gastric ulcer, so that the treatment of the gastric ulcer becomes a hotspot and difficulty of the current medical research.

Irritable Bowel Syndrome (IBS) is a functional bowel disease characterized by abdominal pain or abdominal discomfort with altered bowel habits, which lacks morphological changes and biochemical abnormalities that may explain the symptoms. Research reports in various regions show that IBS is a frequently encountered disease worldwide, the prevalence of IBS in the population of Western countries is 5% -24%, more than 25% of patients are treated with high medical expenses each year, and the quality of life of the patients is affected to different extents. Chronic gastritis and gastric ulcer belong to the categories of epigastric pain, fullness, epigastric upset and the like in traditional Chinese medicine. The common diseases are caused by weakness of the spleen and stomach, or internal injury due to overstrain, transmission of chronic diseases, improper medication and spleen and stomach injury, which can also be caused by emotional internal injury and food and drink injury.

Gastric ulcers are classified into the following five types in traditional Chinese medicine: liver-stomach qi stagnation type, blood stasis and collateral obstruction type, liver-stomach stagnated heat type, spleen and stomach deficiency cold type, and stomach yin deficiency type. The weakness of the spleen and the stomach is the main cause of the disease, qi stagnation and blood stasis are the basic pathological changes of the disease, and the traditional Chinese medicine treatment of the disease is based on strengthening the spleen and tonifying the stomach, regulating qi and dissolving stasis. Epigastric pain was first described in the "Nei Jing". For example, in Ling Shu & Xie zang fu organ disease (cloud): for stomach diseases, abdominal distension and epigastric pain occur with great care. The "Lingshu & distending treatise" is also recorded: for those with gastric distention, abdominal fullness, epigastric pain, smelling of nose, difficulty in eating and defecation. In the Ming and Qing dynasties, the name of epigastric pain is formally established, Wangkntang is mentioned in the "guideline for syndrome treatment", and the former physicians talk about epigastric pain and heart pain together because: "epigastric pain is in the heart, so it is known as heart pain. The name of the stuffiness and fullness is found in the treatise on exogenous febrile disease, and Zhang Zhongjing is explicitly pointed out in the treatise on exogenous febrile disease: "fullness without pain" refers to a feeling of fullness. The differentiation of distention and fullness and accumulation of the chest is also used to initiate the treatment of the heart-fire-purging decoction, which is always the effective method of the later-aged doctors. Noisy sounds were originally observed in Danxi Xin Fa noisy, which day: the noisy condition is the first reason for treating phlegm due to fire. "it is said that food stagnation is accompanied by heat. "Jingyue complete book & noisy": "noisy syndrome, either working or stopped, … … is hunger-like, non-hunger-like, hot-like, non-hot-like, pain-like, and cheerful, famous in the chest". IBS belongs to the categories of abdominal pain, diarrhea, constipation and depression in traditional Chinese medicine. The major pathogenesis of the disease is liver and spleen disorder and liver depression and spleen deficiency, and psychopsychological disorders of different degrees, including anxiety, depression, tension, insomnia and the like, exist in patients with the disease, and seriously affect the occurrence, development and prognosis of the disease. The action mechanism of the traditional Chinese medicine for the treatment of regulating liver and activating spleen is related to the regulation of the brain-intestinal axis function, which is quite consistent with the heart-stomach (heart-intestine) incoordination caused by the unsteadiness of heart-mind in the traditional Chinese medicine. The "three causes of extreme one syndrome & syndrome" treatise: "Xi Shi san, anger Jie, worry Ji, convulsion isolating the movement and visceral qi, and mental consumption dispersing, which indicates that there is a certain relationship between diarrhea and emotion.

In traditional Chinese medicine, the chronic gastritis and the gastric ulcer belong to the categories of gastric upset and epigastric pain, and are divided into deficiency and excess symptoms, wherein the deficiency symptom is caused by deficiency of spleen-stomach yin, and the excess symptom is caused by blood stasis. If the patient has qi deficiency, the gastric acid secretion is reduced and the stomach yin is deficient. The onset of IBS is mostly caused by emotional disorders, which mainly affect the heart spirit, so that the heart spirit disorder is the basis of IBS onset. For this disease, repeated and difficult to detect, spleen qi and kidney yang will be injured for a long time.

In recent years, the number of patients with chronic gastritis, gastric ulcer and irritable bowel syndrome is increasing, and the patients have negative effects on families and society. When western medicine treatment is used, the medicine treatment is generally adopted, and mainly comprises the following steps: the western medicines can effectively inhibit gastric acid, effectively protect gastric mucosa and have the function of eliminating Hp (helicobacter pylori), but the western medicines have large toxic and side effects and are easy to cause adverse reactions such as nausea and vomiting of patients, so that the overall curative effect of treating the gastric ulcer by using the western medicines is not high enough.

Compared with western medicines, the traditional Chinese medicine has small side effect and high safety after long-term administration, has obvious advantages in treating chronic gastritis, gastric ulcer and irritable bowel syndrome, and becomes a research hotspot for treating chronic gastritis, gastric ulcer and irritable bowel syndrome. Through syndrome differentiation and treatment of various doctors, the internal and external environments of the body can be adjusted, the hormone level is balanced, the mental and physical discomfort is improved, the pain of a patient is relieved, and the life quality of the patient is improved.

The traditional Chinese medicine treatment modes are various, and the traditional Chinese medicine treatment method has the conditions of complicated decoction of traditional Chinese medicine decoction pieces, fixed components of the Chinese patent medicine, long treatment process period, incomplete treatment effect, easy repetition and the like. Meanwhile, the decoction process of the traditional Chinese medicine decoction pieces in the prior art can not be controlled, so that the final output is less, the output rate is low, the output quality of the final finished product can not be ensured, and the like.

Disclosure of Invention

In order to solve the problems in the prior art, the invention aims to provide a preparation method of a gastritis eliminating pill.

The technical scheme adopted by the invention is as follows: a preparation method of a gastritis eliminating pill comprises the following steps:

A. selecting cubeb, fructus amomi, cortex magnoliae officinalis and cinnamon according to corresponding proportion, drying, crushing, adding a sterilizing agent for sterilization, and leaving as a standby substance A;

B. selecting Coptidis rhizoma tablet, radix Paeoniae alba, fructus mume preparata, radix Codonopsis, fructus Chebulae, fructus Aurantii parched with bran, Os Sepiae sheath parched with bran and Glycyrrhrizae radix tablet according to corresponding proportion, drying, pulverizing, sterilizing, and reserving as the spare B;

C. and (3) uniformly mixing the standby product A and the standby product B, adding a solidifying agent and a solvent, and drying to obtain a finished product.

The invention provides a preparation method of a gastritis eliminating pill, which controls the water content of each Chinese herbal medicine raw material within a certain range by utilizing a drying technology, thereby ensuring the content of effective components; the crushing technology is utilized to crush the Chinese herbal medicine raw materials, so that the yield of finished products is greatly improved, and meanwhile, the effective components of the Chinese herbal medicine raw materials are kept to be undamaged to the maximum extent; the addition of the solidifying agent and the solvent facilitates the transportation and the use of the obtained finished product, prolongs the service life of the finished product, and has strong safety and stability. The preparation method is simple and convenient to implement and is suitable for mass production.

Preferably, in the step A, when the cubeb, the amomum villosum, the ginger magnolia bark and the cinnamon are selected to be dried, the water content of the cubeb, the amomum villosum, the ginger magnolia bark and the cinnamon after drying is less than 6%;

the drying temperature is 50-60 ℃.

Preferably, in the step A, when the cubeb, the amomum villosum, the ginger magnolia bark and the cinnamon are selected and dried and ground, the ground cubeb, the amomum villosum, the ginger magnolia bark and the cinnamon are sieved by a sieve of 10-24 meshes.

Preferably, in the step a, the sterilizing agent comprises 75% by mass of ethanol;

the total mass of the sterilizing agent accounts for 15-18% of the total mass of the Piper cubeba, the fructus amomi, the cortex magnoliae officinalis and the cortex cinnamomi;

and sterilizing for 3-5 hours.

In the step A, the cubeb, the amomum villosum, the ginger magnolia bark and the cinnamon contain volatile components, are unstable to heat and cannot be sterilized by damp heat, and ethanol sterilization is selected for large-scale production, so that the effect of high-efficiency sterilization can be achieved, and the method is suitable for industrial production.

Preferably, in the step B, when the coptis chinensis slices, the white peony roots, the smoked plums, the codonopsis pilosula, the myrobalan, the bran-fried fructus aurantii, the bran-fried cuttlebone sheaths and the liquorice slices are selected and dried, the water content of the dried coptis chinensis slices, the white peony roots, the smoked plums, the codonopsis pilosula, the myrobalan, the bran-fried fructus aurantii, the bran-fried cuttlebone sheaths and the liquorice slices is less than 5%;

the drying temperature is 60-70 ℃.

Preferably, in the step B, the coptis chinensis slices, the white paeony roots, the prepared dark plums, the codonopsis pilosula, the myrobalan, the bran-fried bitter oranges, the bran-fried cuttlebones and the liquorice slices are selected, dried and crushed, and then the crushed materials are sieved by a sieve of 10 to 24 meshes.

Preferably, in the step B, the sterilization temperature is 110-121 ℃;

and sterilizing for 5-8 minutes.

Preferably, in the step C, the solidifying agent comprises honey;

the solvent comprises water;

the drying temperature is 55-60 ℃;

and the water content of the finished product obtained after drying is less than 8%.

Preferably, in the step C, the mass ratio of the total mass of the spare material A and the spare material B to the mass of the solid forming agent and the mass of the solvent is 10-20:4-8: 1-2.

Preferably, the raw materials comprise the following components in parts by weight:

30-47.6 parts of cubeb litsea, 60-71.4 parts of amomum fruit, 60-71.4 parts of magnolia officinalis with ginger, 30-47.6 parts of cinnamon, 70-95.2 parts of coptis chinensis, 60-71.4 parts of white peony root, 60-71.4 parts of prepared dark plum, 70-95.2 parts of codonopsis pilosula, 70-95.2 parts of myrobalan, 30-47.6 parts of bran-fried fructus aurantii, 30-47.6 parts of bran-fried cuttlebone and 30-47.6 parts of liquorice tablet.

The prescription of the invention takes the cortex magnoliae officinalis as a monarch drug, the cortex cinnamomi and the rhizoma coptidis as ministerial drugs, the fructus amomi, the radix paeoniae alba, the fructus aurantii immaturus fried with bran, the cubeb, the myrobalan, the cuttlebone fried with bran, the smoked plum and the codonopsis pilosula as adjuvant drugs, and the liquorice tablets as conductant drugs. The prescription mainly comprises warming medicines, and has the main treatment principles of strengthening spleen and stomach, promoting qi circulation and relieving pain in treatment, so as to promote the proliferation of gastric mucosa cells, increase gastric acid secretion, relieve the symptom of gastric atrophy and effectively recover the gastrointestinal function of a patient. The Chinese medicinal composition has high cure rate for patients suffering from chronic gastritis, gastric ulcer, irritable bowel syndrome and the like, and has no damage to the physical functions of users.

The invention has the beneficial effects that:

the invention provides a preparation method of a gastritis eliminating pill, which controls the water content of each Chinese herbal medicine raw material within a certain range by utilizing a drying technology, thereby ensuring the content of effective components; the crushing technology is utilized to crush the Chinese herbal medicine raw materials, so that the yield of finished products is greatly improved, and meanwhile, the effective components of the Chinese herbal medicine raw materials are kept to be undamaged to the maximum extent; the addition of the solidifying agent and the solvent facilitates the transportation and the use of the obtained finished product, prolongs the service life of the finished product, and has strong safety and stability. The preparation method is simple and convenient to implement and is suitable for mass production. The prescription takes ginger magnolia bark as a monarch drug, cinnamon and coptis as ministerial drugs, fructus amomi, radix paeoniae alba, bran-fried fructus aurantii, cubeb, myrobalan, bran-fried cuttlebone, prepared dark plum fruit and codonopsis pilosula as adjuvant drugs, and liquorice tablets as messenger drugs. The prescription mainly comprises warming medicines, and has the main treatment principles of strengthening spleen and stomach, promoting qi circulation and relieving pain in treatment, so as to promote the proliferation of gastric mucosa cells, increase gastric acid secretion, relieve the symptom of gastric atrophy and effectively recover the gastrointestinal function of a patient. The Chinese medicinal composition has high cure rate for patients suffering from chronic gastritis, gastric ulcer, irritable bowel syndrome and the like, and has no damage to the physical functions of users.

Drawings

FIG. 1 is a TLC chromatogram of radix Codonopsis in example 2 of the gastritis-treating pill;

FIG. 2 is the TLC chromatogram of the identification of fructus Amomi in example 2 of the gastritis-treating pill;

FIGS. 3 and 4 are TLC identification patterns of Coptidis rhizoma of gastritis-treating pill example 2;

FIG. 5 is the TLC chromatogram of the radix Paeoniae alba of example 2 of the gastritis eliminating pill;

FIG. 6 is a TLC chromatogram of the chebula fruit of the gastritis-treating pill example 2;

FIG. 7 is a thin-layer chromatogram identification spectrum of the ginger-magnolia bark of the gastritis eliminating pill example 2;

FIG. 8 is a thin layer chromatogram identification of the prepared smoked plum of the gastritis-treating pill example 2;

fig. 9 is a thin-layer chromatogram identification spectrum of cinnamon of the gastritis elimination pill example 2;

fig. 10 is a thin layer chromatogram identification spectrum of bran-parched fructus aurantii of example 2 of the gastritis-treating pill;

fig. 11 is a thin layer chromatography chromatogram of piper cubeba of the gastritis elimination pill example 2.

Detailed Description

The present invention is further illustrated below with reference to specific examples. It will be appreciated by those skilled in the art that the following examples, which are set forth to illustrate the present invention, are intended to be part of the present invention, but not to be construed as limiting the scope of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The examples were carried out under the conventional conditions, unless otherwise specified. The reagents used are all conventional products which are commercially available.

Example 1:

a preparation method of a gastritis eliminating pill comprises the following steps:

A. selecting 30 g of cubeb litsea, 60 g of amomum villosum, 60 g of cortex magnoliae officinalis and 30 g of cinnamon according to corresponding proportion, drying at 50 ℃ until the water content of the raw materials is less than 6%, crushing, screening by a 10-mesh screen, adding 75% ethanol, sterilizing for 3 hours, and reserving as a standby substance A;

B. selecting 70 g of coptis chinensis slice, 60 g of white paeony root, 60 g of prepared dark plum, 70 g of codonopsis pilosula, 70 g of myrobalan, 30 g of bran-fried bitter orange, 30 g of bran-fried cuttlebone and 30 g of liquorice slice according to corresponding proportion, drying at 60 ℃ until the water content of each raw material is less than 5%, crushing and screening by a 10-mesh filter screen, sterilizing at 110 ℃ for 5 minutes, and reserving as a spare substance B;

C. mixing the above A and B, adding Mel and water, and drying at 55 deg.C to obtain final product with water content of less than 8%.

Example 2:

A. selecting 47.6 g of cubeb litsea cubeba, 71.4 g of amomum villosum, 71.4 g of cortex magnoliae officinalis and 47.6 g of cinnamon according to corresponding proportion, drying at 60 ℃ until the water content of each raw material is less than 6%, crushing, screening by a 24-mesh filter screen, adding 75% ethanol, sterilizing for 5 hours, and reserving as a standby substance A;

B. selecting 95.2 g of coptis chinensis slice, 71.4 g of white peony root, 71.4 g of prepared dark plum, 95.2 g of codonopsis pilosula, 95.2 g of myrobalan, 47.6 g of bran-fried fructus aurantii, 47.6 g of bran-fried cuttlebone and 47.6 g of liquorice slice according to corresponding proportion, drying at 70 ℃ until the water content of each raw material is less than 5%, crushing, screening by a 24-mesh filter screen, sterilizing at 121 ℃ for 8 minutes, and reserving as a spare B;

C. mixing the above A and B, adding Mel and water, and drying at 60 deg.C to obtain final product with water content of less than 8%.

In the actual preparation process of the above embodiments, in step C, the substance a for standby, the substance B for standby, honey and water are mixed and put into a mixer for uniform mixing, and then put into a granulator for granulation, and the granules are granulated to obtain 3.5mm water-honeyed pills. And then putting the mixture into a granulating machine for granulating for 3-5 minutes, and drying the granulated pills at 55-60 ℃ until the water content is less than 8%. The rejected pellets are then removed by sieving the pellets.

When recommended, 63g of the powder is packaged in each bottle.

The properties of the finished product are as follows: is brown water-honeyed pill; slightly fragrant smell, slightly sweet taste and slightly bitter taste.

The applicable symptoms are as follows: nausea, vomiting, acid regurgitation, heartburn, inappetence, fear of cold in stomach, press preference, etc. caused by intermingled cold and heat, incoordination between spleen and stomach, or chronic gastritis, gastric ulcer, irritable bowel syndrome with the above symptoms.

In the actual operation process of all the embodiments, the selected pulverizer is a Chinese herbal medicine superfine pulverizer, and the type is as follows: JCWF-15A, manufacturer: junchen distance mechanical equipment, Inc. The selection of the type of the pulverizer and the selection of manufacturers can be set according to the actual environment and the actual requirements in the specific implementation process. All the raw materials can be crushed, and the components of the crushed materials are consistent with those of the finished products obtained in the above embodiments after being filtered and sieved, and the method belongs to the protection scope of the invention.

In the actual operation process of all the embodiments, the selected blending device comprises a three-dimensional motion mixer, stainless steel materials with specification models of SYH-30 and SYH-1000, and manufacturers: jiangyin and Rong mechanical Co. The selection of the stirring device is not limited to the above, and all devices which can complete the corresponding stirring work and have no influence on raw materials belong to the protection scope of the invention.

In the practical operation process, the finished product needs to be packaged, and a horizontal packaging machine and an ink-jet printer are respectively selected. The horizontal packaging machine is made of stainless steel, the specification and model are SG-180, and a manufacturer: shanghai plastic packaging science and technology, Inc. The ink jet numbering machine is made of stainless steel, the specification and model are V803-D, and a manufacturer: beijing Oriental Union technologies, Inc.

In the practical operation process of the embodiment, the selected granulating device comprises a high-speed mixing granulator and a swinging granulator. The high-speed mixing granulator is made of stainless steel, the specification and model are GHL-300, and the manufacturer comprises: jiangyin and Rong mechanical Co. The swing granulator is made of stainless steel, has specification and model number of YK-160, and is manufactured by the following manufacturers: jiangyin and Rong mechanical Co. The selection of the granulating device is not limited to the above-mentioned selection, and all devices capable of performing the corresponding granulating operation are within the protection scope of the present invention.

In the practical operation process of the embodiment, the selected drying device comprises a boiling dryer which is made of stainless steel and has the specification model of FG-120, and the manufacturer: jiangyin and Rong mechanical Co. The choice of the drying device is not limited to the above-mentioned ones, and all devices capable of performing the corresponding drying operation are within the scope of the present invention.

In the practical operation process of the above embodiment, the selected granulating device is a granulator made of stainless steel, and the specification and model number of the granulator is YK-160, and the manufacturer: jiangyin and Rong mechanical Co. The selection of the granule finishing device is not limited to the above-mentioned ones, and all devices capable of finishing the corresponding granule finishing work belong to the protection scope of the present invention.

In the actual operation process of all the embodiments, the selected high-temperature sterilization device comprises an ultrahigh-temperature instantaneous sterilizer which is made of stainless steel and has the specification and model number: RP6L10, manufacturer: shanghai Taiwan light tools and equipments Ltd. The selection of the high-temperature sterilization device is not limited to the selection provided above, and all devices which can complete the corresponding high-temperature sterilization work and have no influence on the overall reaction belong to the protection scope of the invention.

Experimental example:

the gastritis-treating pills selected below were dried and made into powder for verification, and the selected finished product was the finished product of example 2.

Thin layer identification of codonopsis pilosula

The method comprises the following steps: taking 20g of the finished product powder of example 2, adding 40ml of methanol, performing ultrasonic treatment for 30 minutes, filtering, evaporating to dryness, dissolving the residue in 20ml of water, extracting with chloroform for 2 times, 20ml each time, combining the extractive solutions, evaporating to dryness, and dissolving the residue in 1ml of methanol to obtain a sample solution. And preparing a radix codonopsis lacking negative sample solution by the same method. Then 0.5g of radix Codonopsis reference material is prepared into reference material solution by the same method. Testing by thin layer chromatography (0502 of the four ministry of the national pharmacopoeia 2015), sucking the three solutions each at 6 μ L, respectively dropping on the same silica gel G thin layer plate, developing with toluene-ethyl acetate-formic acid (20:8:0.5) as developing agent, taking out, air drying, spraying with 10% sulphuric acid ethanol solution, and heating at 105 deg.C until the spots are clearly developed. Thin layer conditions: temperature: 24.9 ℃; humidity: 72 percent; developing agent: toluene-ethyl acetate-carboxylic acid (20:8: 0.5); thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: 6 mu L of the solution; and (6) inspection: spraying 10% ethanol sulfate solution, and heating at 105 deg.C until the spots are clear.

Reference numerals 1 to 3 in FIG. 1: example 2 finished powder test article solution; 4: radix Codonopsis reference medicinal solution; 5: codonopsis pilosula negative sample solution.

As shown in FIG. 1, the color spectrum of the test sample shows spots of the same color as the color spectrum of the negative sample, and the control sample shows no spots.

Thin layer identification of fructus Amomi and fructus Amomi

The method comprises the following steps: 20g of the product powder obtained in example 2 was taken, 40ml of petroleum ether (60 to 90 ℃) was added, the mixture was refluxed for 1 hour, filtered and evaporated, and the residue was dissolved in 1ml of petroleum ether (60 to 90 ℃) to prepare a sample solution. And preparing a negative sample solution by the same method by taking another fructus amomi lacking negative sample. And then 1g of fructus amomi reference medicinal material is taken, and 20ml of petroleum ether (60-90 ℃) is added to prepare a reference medicinal material solution in the same way. Performing thin layer chromatography (0502 of general rules of the four parts of the book of Chinese pharmacopoeia 2015), sucking 8 μ L of the three solutions, respectively dropping on the same silica gel G thin layer plate, developing with cyclohexane-ethyl acetate (22:1) as developing agent, taking out, air drying, spraying 5% vanillin-sulfuric acid solution for color development, and heating at 105 deg.C until the spots are clearly developed. Thin layer conditions: temperature: 24.0 ℃; humidity: 68 percent; developing agent: cyclohexane-ethyl acetate (22: 1); thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: 8 mu L of the solution; and (6) inspection: spraying 5% vanillin sulfuric acid solution for color development, and heating at 105 deg.C until the spots are clearly developed.

The numbers in fig. 2: 1-3: example 2 finished powder test article solution; 4: fructus Amomi reference medicinal solution; 5: fructus amomi negative sample solution.

As shown in FIG. 2, the test chromatogram showed spots of the same color at the positions corresponding to those of the control chromatogram, but the negativity was interfered.

Thin layer identification of three, coptis

The method comprises the following steps: 10g of the finished product powder in the example 2 is taken, 40ml of methanol is added, ultrasonic treatment is carried out for 30 minutes, and filtration is carried out, and the filtrate is taken as a test solution. Taking another negative sample lacking Coptidis rhizoma, and preparing a negative sample solution by the same method. Then, the product is processedTaking 1g of Coptidis rhizoma control medicinal material, adding 20ml of methanol, and making into control medicinal solution by the same method. Performing thin layer chromatography (0502 of the four ministerial rules of the design reside in the Chinese pharmacopoeia 2015), collecting the sample solution and negative sample solution 4 μ L respectively, adding control solution 2 μ L, and spotting on the same silica gel G thin layer plate, 2 parts, and adding 1 part^#Ethyl acetate-acetone-formic acid-water (5: 1), 2^#Developing with n-butanol-glacial acetic acid-water (7: 1: 2) as developing agent, taking out, air drying, and inspecting under ultraviolet lamp (365 nm). Thin layer conditions: temperature: 24.8 ℃; humidity: 75 percent; developing agent: ethyl acetate-acetone-formic acid-water (5: 1); thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: the sample solution and the negative sample solution are respectively 4 mu L, and the contrast medicinal material solution is 2 mu L; and (6) inspection: inspection was performed under an ultraviolet lamp (365 mn).

Reference numbers in fig. 3: 1-3: example 2 finished powder test article solution; 4: rhizoma Coptidis as reference material solution; 5: coptis negative sample solution.

Thin layer conditions: temperature: 24.8 ℃; humidity: 75 percent; developing agent: n-butanol-glacial acetic acid-water (7: 1: 2); thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: the sample solution and the negative sample solution are respectively 4 mu L, and the contrast medicinal material solution is 2 mu L; and (6) inspection: inspection was performed under an ultraviolet lamp (365 mn).

Reference numbers in fig. 4: 1-3: example 2 finished powder test article solution; 4: coptis chinensis control medicinal material solution 5: coptis negative sample solution.

The results are shown in FIGS. 3 and 4, 1^#、2^#No. 1 developing agent, spots of the same color appear in the chromatogram of the test solution at the positions corresponding to those of the chromatogram of the reference solution, and negativity is not interfered, but 1^#Sample No. developer with better main spot separation, therefore, determination 1^#The number developing agent is a developing system for thin layer identification of rhizoma Coptidis, and is listed as standard.

Thin layer identification of four and white peony roots

The method comprises the following steps: taking 25g of the finished product powder in the example 2, adding 40ml of ethanol, carrying out ultrasonic treatment for 15 minutes, filtering, evaporating to dryness, and dissolving residues in 1ml of ethanol to obtain a test solution. Preparing a negative sample solution by the same method except for preparing a negative sample lacking the white paeony root. Performing thin layer chromatography (0502 of the four parts of the book of Chinese pharmacopoeia 2015), collecting 10 μ L of each of the two solutions, adding 1G of radix Paeoniae alba as a control medicinal material, adding 20ml of ethanol, preparing 10 μ L of the control medicinal material solution by the same method, respectively dropping on the same silica gel G thin layer plate, developing with chloroform-ethyl acetate-methanol-formic acid (40: 5: 10: 0.2) as developing agent, taking out, air drying, spraying with 5% vanillin-sulfuric acid solution, and heating at 105 deg.C until the spots are clearly developed. Thin layer conditions: temperature: 25.3 ℃; humidity: 65 percent; developing agent: chloroform-ethyl acetate-methanol-formic acid (40: 5: 10: 0.2); thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: 10 mu L of the solution; and (6) inspection: spraying 5% vanillin-sulfuric acid solution, and heating at 105 deg.C until the color of spots is clear.

Reference numbers in fig. 5: 1-3: example 2 finished powder test article solution; 4: white peony root reference medicinal solution; 5: white peony root negative sample solution. The result is shown in fig. 5, spots with the same color appear on the chromatogram of the test solution at the corresponding positions of the chromatogram of the control solution, the negative is not interfered, and the main spot is clearly visible.

Wu, thin layer identification of myrobalan

The method comprises the following steps: taking 15g of the finished product powder of the example 2, adding 40ml of absolute ethyl alcohol, carrying out ultrasonic treatment for 30 minutes, filtering, evaporating to dryness, and adding 1ml of absolute ethyl alcohol to the residue to dissolve the residue to obtain a test solution. And preparing a negative sample solution by the same method by taking a negative sample lacking the myrobalam. Performing thin layer chromatography (0502 of the four ministerial general rules of the design reside in the Chinese pharmacopoeia 2015), collecting 6 μ L of the above two solutions, collecting 1G of fructus Chebulae as control material, preparing 6 μ L of control material solution by the same method, respectively dropping on the same silica gel G thin layer plate, developing with chloroform-ethyl acetate-formic acid (3: 2:1) as developing agent, taking out, air drying, spraying 10% ethanol sulfate solution, and heating at 105 deg.C for 5 min. Thin layer conditions: temperature: 24.3 ℃; humidity: 67%; developing agent: chloroform-ethyl acetate-formic acid (3: 2: 1); thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: 6 mu L of the solution; and (6) inspection: spraying 10% ethanol sulfate solution, and heating at 105 deg.C until the spots are clear.

Reference numbers in fig. 6: 1-3: example 2 finished powder test article solution; 4: myrobalan reference medicinal solution; 5: myrobalan negative sample solution.

As shown in FIG. 6, the test chromatogram showed the same color spot at the position corresponding to the control chromatogram, and the test chromatogram was non-interfering.

Thin layer identification of six, ginger magnolia bark

The method comprises the following steps: 10g of the finished product powder in the example 2 is taken, 30ml of methanol is added, ultrasonic treatment is carried out for 30 minutes, and filtration is carried out, and the filtrate is taken as a test solution. And preparing a negative sample solution from the ginger-deficient magnolia officinalis negative sample by the same method. Performing thin layer chromatography (0502 of the four ministerial rules of the design reside in the Chinese pharmacopoeia 2015), sucking 6 μ L of the above two solutions, collecting 1G of cortex Magnolia officinalis as control, preparing 6 μ L of control solution by the same method, respectively dropping on the same silica gel G thin layer plate, developing with toluene-methanol (17: 2) as developing agent, taking out, air drying, and inspecting under ultraviolet lamp (254 nm). Thin layer conditions: temperature: 24.5 ℃; humidity: 62 percent; developing agent: toluene-methanol (17: 2); thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: 6 mu L of the solution; and (6) inspection: inspecting under 254nm of ultraviolet light.

Reference numbers in fig. 7: 1-3: example 2 finished powder test article solution; 4: ginger magnolia bark contrast medicinal solution; 5: ginger magnolia bark negative sample solution.

As shown in FIG. 7, the test chromatogram showed the same color spot at the corresponding position of the control chromatogram, and the test chromatogram was non-interfering.

Thin layer identification of seven, prepared dark plum

The method comprises the following steps: taking 25g of the finished product powder in example 2, adding 50ml of methanol, carrying out ultrasonic treatment for 30 minutes, filtering, evaporating to dryness, adding 10ml of water into residue for dissolving, extracting with diethyl ether for 2 times, 20ml each time, combining extracting solutions, evaporating to dryness, adding 15ml of petroleum ether (30-60 ℃) into residue, soaking for 2 minutes, discarding petroleum ether solution, and adding 1ml of absolute ethyl alcohol for dissolving to obtain a sample solution. And preparing a negative sample solution by the same method by taking a deficient dark plum negative sample. Taking a dark plum control medicinal material solution under the first item of the method, performing a test by thin-layer chromatography (0502 of the four ministry of the university in the version of Chinese pharmacopoeia 2015), sucking 10 mu L of each of the three solutions, respectively dropping the solution on a same silica gel G thin-layer plate, developing by taking cyclohexane-trichloromethane-ethyl acetate-formic acid (20: 5: 8: 0.1) as a developing agent, taking out, drying in the air, spraying a 10% sulfuric acid ethanol solution, heating at 105 ℃ for 5 minutes, and viewing by placing under an ultraviolet lamp (365 nm). Thin layer conditions: temperature: 24.4 ℃; humidity: 66 percent; developing agent: cyclohexane-trichloromethane-ethyl acetate-formic acid (20: 5: 8: 0.1); thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: 10 mu L of the solution; and (6) inspection: spraying 10% ethanol sulfate solution, heating at 105 deg.C for 5 min, and inspecting under 365nm ultraviolet lamp.

Reference numbers in fig. 8: 1-3: example 2 finished powder test article solution; 4: preparing a dark plum reference medicinal material solution; 5: and preparing a dark plum negative sample solution.

As shown in FIG. 8, the test chromatogram showed the same color spot at the corresponding position of the control chromatogram, and the test chromatogram was non-interfering.

Eighthly, thin-layer identification of cinnamon

The method comprises the following steps: 20g of the finished product powder in the example 2 is taken, 40ml of ethanol is added, cold soaking is carried out for 30 minutes, shaking is carried out at any time, filtering is carried out, and the filtrate is taken as a test solution. And preparing a negative sample solution by the same method from a lean cinnamon negative sample. Performing thin-layer chromatography (0502 of the four ministerial rules of the United states of medicine of China pharmacopoeia 2015), sucking 8 μ L of each of the two solutions, taking 1G of cinnamon as a reference medicinal material, preparing 8 μ L of the reference medicinal material solution by the same method, respectively dropping the solution on the same silica gel G thin-layer plate, developing by using petroleum ether (60-90 ℃) and ethyl acetate (17: 3) as developing agents, taking out, drying in the air, spraying dinitrophenylhydrazine ethanol solution, and inspecting in the sunlight. Thin layer conditions: temperature: 24.4 ℃; humidity: 66 percent; developing agent: n-butanol-glacial acetic acid-water (4: 1) thin layer plates: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: 2 mu L of the solution; and (6) inspection: spraying with 0.2% ninhydrin ethanol solution, and heating at 105 deg.C until the spots are clearly developed.

Reference numbers in fig. 9: 1-3: example 2 finished powder test article solution; 4: cinnamon reference medicinal material solution; 5: cinnamon negative sample solution.

The result is shown in FIG. 9, the test chromatogram shows the same color spot at the corresponding position of the control chromatogram, and the negative is non-interference, so the method is included in the standard.

Thin layer identification of fructus Aurantii stir-fried with bran

The method comprises the following steps: 15g of the powder obtained in example 2 was added with 30ml of methanol, sonicated for 30 minutes, filtered, evaporated to dryness, and the residue was dissolved in 5ml of methanol to give a sample solution. Another negative sample of fructus Aurantii parched with bran is prepared into negative sample solution by the same method. Performing thin layer chromatography (0502 of the four ministerial rules of the science of Chinese pharmacopoeia 2015), sucking 4 μ L of the two solutions, respectively, dropping 4 μ L of fructus Aurantii control solution on the same silica gel G thin layer plate, developing with chloroform-methanol-water (13: 8: 2) lower layer solution as developing agent, taking out, air drying, spraying 2% aluminum trichloride ethanol solution, heating at 105 deg.C for 5 min, and inspecting under ultraviolet lamp (365 nm). Thin layer conditions: temperature: 25.4 ℃; humidity: 68 percent; developing agent: chloroform-methanol-water (13: 8: 2) lower layer solution; thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: 4 mu L of the solution; and (6) inspection: spraying 2% aluminum trichloride ethanol solution, heating at 105 deg.C for 5 min, and inspecting under ultraviolet lamp (365 nm).

Reference numbers in fig. 10: 1-3: example 2 finished powder test article solution; 4: fructus Aurantii control solution parched with bran; 5: bran-fried fructus aurantii negative sample solution.

As shown in FIG. 10, the test chromatogram showed the same color spot as the control chromatogram, and the test chromatogram was negative without interference, so the method was included in the standard.

Thin layer identification of ten, two cubeb

The method comprises the following steps: 10g of the finished product powder in the example 2 is taken, 30ml of petroleum ether (60-90 ℃) is added, ultrasonic treatment is carried out for 15 minutes, and filtration is carried out to obtain a sample solution. And preparing a negative sample solution by the same method by taking another cubeb lack negative sample. 0.5g of cubeb litsea cubeba reference medicinal material is prepared into a reference medicinal material solution by the same method. Performing thin-layer chromatography (0502 of general rules of the four parts of the year 2015 in the Chinese pharmacopoeia) test, sucking 6 μ L of each of the three solutions, respectively dropping on the same silica gel G thin-layer plate, developing with petroleum ether (60-90 ℃) and diethyl ether (1: 1) as developing agent, taking out, air drying, spraying with 10% sulfuric acid ethanol solution, and heating at 105 deg.C until the spots are clearly developed. Thin layer conditions: temperature: 24.3 ℃; humidity: 68 percent; developing agent: petroleum ether (60-90 ℃) and diethyl ether (1: 1); thin-layer plate: qingdao marine silica gel G thin-layer plate; sample application mode: manual contact type sample application; sample amount of spotting: 6 mu L of the solution; and (6) inspection: spraying 10% ethanol sulfate solution, and heating at 105 deg.C until the spots are clear.

Reference numbers in fig. 11: 1-3: example 2 finished powder test article solution; 4: a piper cubeba reference medicinal solution; 5: cubeb negative sample solution. As shown in FIG. 11, the test chromatogram showed the same color spot as the control chromatogram, but the negative color was interfered, so this method was not included in the standard.

While particular embodiments of the present invention have been illustrated and described, it will be appreciated that the present invention is not limited to the above-described alternative embodiments, and that various other forms of product may be devised by anyone in light of the present invention. The foregoing detailed description should not be construed as limiting the scope of the invention, and it will be understood by those skilled in the art that modifications may be made to the technical solutions described in the foregoing embodiments, or that equivalent substitutions may be made to some or all of the technical features thereof, without departing from the spirit and scope of the invention, and that these modifications or substitutions may not substantially depart from the essence of the corresponding technical solutions.

Claims

1. A preparation method of the gastritis eliminating pill is characterized by comprising the following steps:

2. The method for preparing a gastritis eliminating pill according to claim 1, wherein in the step A, when the cubeb, the amomum villosum, the ginger magnolia bark and the cinnamon are selected to be dried, the water content of the cubeb, the amomum villosum, the ginger magnolia bark and the cinnamon is less than 6 percent after drying;

the drying temperature is 50-60 ℃.

3. The method for preparing gastritis eliminating pills according to claim 1, wherein in the step a, when cubeb, amomum villosum, magnolia cortex zingiberis and cinnamon are selected and dried and pulverized, the pulverized material is sieved by 10-24 meshes.

4. The method for preparing a gastritis eliminating pill according to claim 1, wherein in the step a, the sterilizing agent includes 75% by mass of ethanol;

and sterilizing for 3-5 hours.

5. The preparation method of a gastritis-eliminating pill according to claim 1, wherein in the step B, when the coptis chinensis tablet, the white peony root, the prepared dark plum, the codonopsis pilosula, the myrobalan, the bran-fried fructus aurantii, the bran-fried cuttlebone sheath and the liquorice tablet are selected and dried, the water content of the dried coptis chinensis tablet, the white peony root, the prepared dark plum, the codonopsis pilosula, the myrobalan, the bran-fried fructus aurantii, the bran-fried cuttlebone sheath and the liquorice tablet is less than 5%;

the drying temperature is 60-70 ℃.

6. The method for preparing a gastritis eliminating pill according to claim 1, wherein in the step B, the coptis chinensis slices, the white peony roots, the prepared dark plums, the codonopsis pilosula, the myrobalan, the bran-fried fructus aurantii, the bran-fried cuttlebone and the liquorice slices are selected, dried, crushed, and sieved with a sieve of 10-24 meshes.

7. The method for preparing a gastritis eliminating pill as claimed in claim 1, wherein in the step B, the sterilization temperature is 110 ℃ and 121 ℃;

and sterilizing for 5-8 minutes.

8. The method for preparing a gastritis eliminating pill according to claim 1, wherein in the step C, the solidifying agent includes honey;

the solvent comprises water;

the drying temperature is 55-60 ℃;

9. The method for preparing gastritis eliminating pills according to claim 1, wherein in the step C, the mass ratio of the total mass of the ready-to-use substance a and the ready-to-use substance B to the mass of the solid preparation and the mass of the solvent is 10-20:4-8: 1-2.

10. The preparation method of the gastritis eliminating pill according to claim 1, wherein the preparation method comprises the following raw materials in parts by weight: